FEED.US ENvue Medical Inc.
- Market cap
- USD 349K
- P/E
- -
- P/B
- 0.01x
- ROE
- -56.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is FEED.US undervalued?
Graham numberThe Graham number of ENvue Medical Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ENvue Medical Inc. fundamental analysis
No fundamental analysis for ENvue Medical Inc. yet.
ENvue Medical Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ENvue Medical Inc.
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinar…
Full company profileENvue Medical Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ENvue Medical Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 229K | 239K | 318K | 530K | 623K | 1.70M | 752K | 2.28M | 2.56M | 2.55M | 1.78M |
| Gross Profit | 141K | 151K | 160K | 281K | 214K | 770K | 167K | 1.54M | 1.51M | 153K | -642K |
| Operating Income | -2.32M | -3.09M | -4.30M | -5.15M | -4.72M | -5.68M | -5.01M | -3.44M | -3.58M | -11.7M | -18.4M |
| EBITDA | -2.69M | -3.64M | -4.28M | -5.75M | -4.16M | -14.2M | -5.41M | -3.55M | -3.69M | -17.6M | -17.6M |
| Net Income | -2.83M | -5.81M | -4.15M | -5.79M | -4.33M | -14.3M | -5.45M | -3.71M | -3.71M | -18.2M | -17.4M |
| EPS | -16,364 | -30,883 | -17,025 | -22,030 | -11,090 | -14,986 | -5,068 | -2,799 | -1,647 | -254 | -34 |
| Balance Sheet | |||||||||||
| Total Assets | 494K | 4.87M | 1.58M | 2.04M | 8.23M | 8.62M | 5.88M | 6.67M | 3.63M | 41.1M | 38.4M |
| Total Liabilities | 2.99M | 1.23M | 1.12M | 688K | 5.84M | 2.31M | 2.65M | 2.69M | 3.00M | 7.63M | 7.65M |
| Shareholders' Equity | -2.50M | 3.63M | 463K | 1.35M | 2.39M | 6.31M | 3.23M | 3.99M | 627K | 33.5M | 30.8M |
| Cash & Short-term Investments | 106K | 4.36M | 896K | 1.34M | 7.53M | 7.74M | 2.71M | 3.28M | 752K | 4.22M | 1.14M |
| Total Debt | - | - | - | - | 31.0K | 49.0K | 81.0K | 5.00K | 116K | 1.20M | 1.31M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.53M | -2.18M | -3.55M | -3.87M | -3.39M | -4.37M | -7.04M | -3.60M | -2.52M | -9.37M | -14.0M |
| Capital Expenditure | 8.00K | 0.00 | 8.00K | 0.00 | 2.00K | 3.00K | 3.00K | 1.00K | 3.00K | 60.0K | 88.0K |
| Free Cash Flow | -1.54M | -2.18M | -3.56M | -3.87M | -3.39M | -4.37M | -7.04M | -3.60M | -2.52M | -9.43M | -14.1M |
| Ratios | |||||||||||
| ROE | - | -159.8% | -897.2% | -429.8% | -180.7% | -226.2% | -168.5% | -93.1% | -590.9% | -54.3% | -56.7% |
| ROA | -573.1% | -119.3% | -262.9% | -284.6% | -52.6% | -165.6% | -92.7% | -55.6% | -102.1% | -44.2% | -45.4% |
| Net Profit Margin | -1,236.2% | -2,429.3% | -1,306.3% | -1,093.2% | -694.2% | -842.6% | -724.5% | -162.5% | -144.8% | -712.3% | -977.7% |
| Debt to Equity | - | - | - | - | 0.01x | 0.01x | 0.03x | 0.00x | 0.19x | 0.04x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ENvue Medical Inc. dividends
ENvue Medical Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:12 on Sep 1, 2026.
Who owns ENvue Medical Inc.
- Insiders 16.41%
- Institutions 1.03%
- Public & others 82.56%
- Shares outstanding 924K
- Free float 859K
Top funds holding FEED.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 14.8K | 0.13% | 0.00% | Aug 2026 |
Top institutions holding FEED.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 116K | 1.04% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 95.3K | 0.86% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 37.6K | 0.34% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 15.5K | 0.14% | -31.01% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 10.3K | 0.09% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 10.0K | 0.09% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 4.78K | 0.04% | +69.60% | Jun 2026 |
| Global Retirement Partners, LLC. | 1.60K | 0.01% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 189.00 | 0.00% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 85.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 45.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 15.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| International Assets Investment Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Schonfeld Strategic Advisors LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Poehling Capital Management Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| FMR Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
ENvue Medical Inc. company profile
- Company name
- ENvue Medical Inc.
- Ticker
- FEED.US
- Exchange
- USA Stocks
- Listed since
- Jun 13, 2017
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 12
- Fiscal year end
- December
- Address
- 969 Pruitt Ave, Tyler, TX, United States, 77569
- Phone
- 914-233-3004
- Website
- envuemed.com
About ENvue Medical Inc.
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Tyler, Texas.
ENvue Medical Inc. management
4- Dr. Doron Robert Besser M.D.CEO, President & Director · born 1969
- Ms. Nicole Fernandez-McGovern CPAChief Financial Officer · born 1973
- Ms. Rita SilberbergSenior VP & Chief Accounting Officer · born 1975
- Mr. Frederick Karl ReuningChief Marketing Officer · born 1955